The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP‐induced receptor signaling and platelet aggregation
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Retinal Conformation and its Environment in Rhodopsin in Light of a New 2.2 Å Crystal Structure
Okada, T., Sugihara, M., Bondar, A.-N., Elstner, M., Entel, P., & Buss, V. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.07.044 · Cited by 1,049
Research works printed but not linked: 25
- Presland, 2005, Identifying novel modulators of G protein‐coupled receptors via interaction at allosteric sites, Curr Opin Drug Discov Devel, 8, 567
- Langmead, 2006, Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox, Trends Pharmacol Sci, 27, 475, 10.1016/j.tips.2006.07.009 · DOI
- Gao, 2005, Allosteric modulation of the adenosine family of receptors, Mini-Rev Med Chem, 5, 545, 10.2174/1389557054023242 · DOI
- Holzgrabe, 2006, Allosteric modulators and selective agonists of muscarinic receptors, J Mol Neurosci, 30, 165, 10.1385/JMN:30:1:165 · DOI
- Maksay, 2005, Allosteric modulation of 5‐HT3 serotonin receptors, Eur J Pharmacol, 514, 17, 10.1016/j.ejphar.2005.03.019 · doi:10.1016/j.ejphar.2005.03.019
- Price, 2005, Allosteric modulation of the cannabinoid CB1 receptor, Mol Pharmacol, 68, 1484, 10.1124/mol.105.016162 · DOI · Paper page
- Gao, 2004, 2,2′‐Pyridylisatogen tosylate antagonizes P2Y1 receptor signaling without affecting nucleotide binding, Biochem Pharmacol, 68, 231, 10.1016/j.bcp.2004.02.039 · DOI
- Gaarder, 1961, Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets, Nature, 192, 531, 10.1038/192531a0 · DOI · Paper page
- Fagura, 1998, P2Y1‐receptors in human platelets which are pharmacologically distinct from P2YADP‐receptors, Br J Pharmacol, 124, 157, 10.1038/sj.bjp.0701827 · doi:10.1038/sj.bjp.0701827
- Hollopeter, 2001, Identification of the platelet ADP receptor targeted by antithrombotic drugs, Nature, 409, 202, 10.1038/35051599 · DOI · Paper page
- Takasaki, 2001, Molecular cloning of the platelet P2T(AC) ADP receptor: pharmacological comparison with another ADP receptor, the P2Y(1) receptor, Mol Pharmacol, 60, 432, 10.1016/S0026-895X(24)12604-1 · DOI
- Cattaneo, 2007, Platelet P2 receptors: old and new targets for antithrombotic drugs, Expert Rev Cardiovasc Ther, 5, 45, 10.1586/14779072.5.1.45 · DOI
- Van Giezen, 2005, Preclinical and clinical studies with selective reversible direct P2Y12 antagonists, Semin Thromb Hemost, 31, 195, 10.1055/s-2005-869525 · DOI · Paper page
- Springthorpe, 2007, From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis, Bioorg Med Chem Lett, 17, 6013, 10.1016/j.bmcl.2007.07.057 · DOI · Paper page
- Van Giezen, 2008, Optimizing platelet inhibition, Eur Heart J Suppl, 10, D23, 10.1093/eurheartj/sun009 · doi:10.1093/eurheartj/sun009
- Husted, 2006, Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double‐blind comparison to clopidogrel with aspirin, Eur Heart J, 27, 1038, 10.1093/eurheartj/ehi754 · DOI · Paper page
- Cannon, 2007, Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non‐ST segment elevation acute coronary syndrome, J Am Coll Cardiol, 50, 1844, 10.1016/j.jacc.2007.07.053 · DOI · Paper page
- Van Giezen, 2008, AZD6140 displays over 100‐fold higher affinity for the P2Y12 receptor vs AZ11702105, a compound indistinguishable from the active metabolite of prasugrel, and is a more potent inhibitor of ADP‐induced platelet aggregation, Arterioscler Thromb Vasc Biol, 28, e139
- Sali, 1993, Comparative protein modelling by satisfaction of spatial restraints, J Mol Biol, 234, 779, 10.1006/jmbi.1993.1626 · DOI · Paper page
- McMartin, 1997, QXP: powerful, rapid computer algorithms for structure‐based drug design, J Comput Aided Mol Des, 11, 333, 10.1023/A:1007907728892 · DOI · Paper page
- Mills, 1992, Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase, Arterioscler Thromb, 12, 430, 10.1161/01.ATV.12.4.430 · doi:10.1161/01.atv.12.4.430
- Savi, 2006, The active metabolite of clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts, Proc Natl Acad Sci USA, 103, 11069, 10.1073/pnas.0510446103 · DOI · Paper page
- Marteau, 2003, Pharmacological characterization of the human P2Y13 receptor, Mol Pharmacol, 64, 104, 10.1124/mol.64.1.104 · DOI · Paper page
- Ferguson, 2008, 2‐Aminothienopyridazines as novel adenosine A1 receptor allosteric modulators and antagonists, J Med Chem, 51, 6165, 10.1021/jm800557d · DOI
- Storey, 2007, Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes, J Am Coll Cardiol, 50, 1852, 10.1016/j.jacc.2007.07.058 · DOI · Paper page
Cited by
Gurbel, P. A., Bliden, K. P., Butler, K., Tantry, U. S., Gesheff, T., Wei, C., Teng, R., Antonino, M. J., Patil, S. B., Karunakaran, A., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.912550 · Cited by 1,159
Cannon, C. P., Harrington, R. A., James, S., Ardissino, D., Becker, R. C., Emanuelsson, H., Husted, S., Katus, H., Keltai, M., Khurmi, N. S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62191-7 · Cited by 664
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
Becker, R. C., Bassand, J. P., Budaj, A., Wojdyla, D. M., James, S. K., Cornel, J. H., French, J., Held, C., Horrow, J., Husted, S., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr422 · Cited by 383
Ferraris, V. A., Saha, S. P., Oestreich, J. H., Song, H. K., Rosengart, T., Reece, T. B., Mazer, C. D., Bridges, C. R., Despotis, G. J., Jointer, K., et al. (2012) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2012.07.086 · Cited by 293
Metadata
- Authors
- VAN GIEZEN, J. J. J., NILSSON, L., BERNTSSON, P., WISSING, B. M., GIORDANETTO, F., TOMLINSON, W., & GREASLEY, P. J.
- Venue
- Journal of Thrombosis and Haemostasis
- Publisher
- Elsevier BV
- Published
- 2009-09
- Volume
- 7
- Issue
- 9
- Pages
- 1556-1565
- ISSN
- 1538-7836 (ISSN-L)
- OpenAlex
- W2069561061
- Cited by
- 284
- References
- 1
- FWCI
- 12.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 4848 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP‐induced receptor signaling and platelet aggregation. https://app.cochat.ai/papers/10.1111/j.1538-7836.2009.03527.x
- The paper
- VAN GIEZEN, J. J. J., NILSSON, L., BERNTSSON, P., WISSING, B. M., GIORDANETTO, F., TOMLINSON, W., & GREASLEY, P. J. (2009). Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP‐induced receptor signaling and platelet aggregation. Journal of Thrombosis and Haemostasis. https://doi.org/10.1111/j.1538-7836.2009.03527.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.